Clinical Trial Update: Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of SL-172154 (SIRPα-Fc-CD40L) in ovarian, fallopian tube, and primary peritoneal cancers has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• SL-172154 (SIRPα-Fc-CD40L)

Snippet

Sponsor: Shattuck Labs, Inc. | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Status: COMPLETED | Results posted: 2025-01-30